Clinical outcomes of complex lesions treated with an abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent.
BACKGROUND
The Firehawk stent (Shanghai MicroPort Medical Group, Shanghai, China), a novel biodegradable polymer sirolimus-eluting coronary stent has been evaluated in the randomized TARGET I trial in which low-risk patients were enrolled with strict eligibility criteria. Recently, the TARGET All Comers study has shown similar results of the Firehawk compared to the XIENCE stent (Abbott Vascular, Santa Clara). However, clinical outcomes in high-risk patients are unclear.


METHODS
The TARGET All Comer study was a randomized trial that assigned patients to either Firehawk or XIENCE implantation. This TARGET AC subanalysis sought to evaluate the 2 year clinical outcomes of patients according to two risk groups; patients meeting all inclusion criteria and no exclusion criteria of the TARGET I trial were classified as "low-risk," while their counterparts were classified as "high-risk." The primary endpoint was target lesion failure.


RESULTS
A total of 1,585 patients were included, of which 1,334 (84%) were classified as high-risk. At 2 years, the high-risk group had a significantly higher rate of TLF than the low-risk group (9.5% vs. 3.6%, p = .003), mainly driven by increased target vessel myocardial infarction (6.3% vs. 2.4%, p = .02). The Firehawk and XIENCE had no significant differences in TLF among both low-risk (3.1% vs. 4.2%, p = .66) and high-risk (9.9% vs. 9.1%, p = .57) patients.


CONCLUSIONS
High-risk patients had worse clinical outcomes at 2 years in the TARGET All Comer study. Outcomes with the Firehawk were similar to the XIENCE stent among both low-risk and high-risk patients at 2 years.
['Saito|Yuichi|Y|0000-0003-3574-0685', 'Baumbach|Andreas|A|', 'Wijns|William|W|', 'Xu|Bo|B|0000-0002-1165-7302', 'Kelbaek|Henning|H|', 'Zheng|Ming|M|', 'Morel|Marie-Angèle|MA|', 'Anderson|Richard|R|0000-0003-0582-1628', 'Schächinger|Volker|V|', 'Lansky|Alexandra|A|0000-0001-8002-7497', '|||']
D020341:Absorbable Implants D000368:Aged D002317:Cardiovascular Agents D003324:Coronary Artery Disease D054855:Drug-Eluting Stents D005060:Europe D000068338:Everolimus D005260:Female D006801:Humans D008297:Male D008875:Middle Aged D062645:Percutaneous Coronary Intervention D011474:Prosthesis Design D018570:Risk Assessment D012307:Risk Factors D013997:Time Factors D016896:Treatment Outcome
everolimus-eluting stent Firehawk eligibility drug-eluting stent